Andrzej S Krolewski

List of Publications by Year
in descending order

48 papers	6,106 citations	147801 31 h-index	233421 45 g-index
48 all docs	48 docs citations	48 times ranked	6169 citing authors

#	Article	IF	Citations
1	The changing natural history of nephropathy in type I Diabetes. American Journal of Medicine, 1985, 78, 785-794.	1.5	795
2	Regression of Microalbuminuria in Type 1 Diabetes. New England Journal of Medicine, 2003, 348, 2285-2293.	27.0	719
3	Mutations in NEUROD1 are associated with the development of type 2 diabetes mellitus. Nature Genetics, 1999, 23, 323-328.	21.4	551
4	Circulating TNF Receptors 1 and 2 Predict ESRD in Type 2 Diabetes. Journal of the American Society of Nephrology: JASN, 2012, 23, 507-515.	6.1	388
5	Blood Kidney Injury Molecule-1 Is a Biomarker of Acute and Chronic Kidney Injury and Predicts Progression to ESRD in Type I Diabetes. Journal of the American Society of Nephrology: JASN, 2014, 25, 2177-2186.	6.1	341
6	Microalbuminuria and the Risk for Early Progressive Renal Function Decline in Type 1 Diabetes. Journal of the American Society of Nephrology: JASN, 2007, 18, 1353-1361.	6.1	325
7	Circulating TNF Receptors 1 and 2 Predict Stage 3 CKD in Type 1 Diabetes. Journal of the American Society of Nephrology: JASN, 2012, 23, 516-524.	6.1	307
8	A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes. Nature Medicine, 2019, 25, 805-813.	30.7	260
9	Early Progressive Renal Decline Precedes the Onset of Microalbuminuria and Its Progression to Macroalbuminuria. Diabetes Care, 2014, 37, 226-234.	8.6	219
10	Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study. Kidney International, 2014, 85, 1214-1224.	5.2	182
11	Progressive Renal Decline: The New Paradigm of Diabetic Nephropathy in Type 1 Diabetes. Diabetes Care, 2015, 38, 954-962.	8.6	176
12	Risk for ESRD in Type 1 Diabetes Remains High Despite Renoprotection. Journal of the American Society of Nephrology: JASN, 2011, 22, 545-553.	6.1	166
13	Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes. Kidney International, 2017, 91, 1300-1311.	5.2	159
14	A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes. Diabetes, 2018, 67, 1414-1427.	0.6	136
15	High-Normal Serum Uric Acid Is Associated with Impaired Glomerular Filtration Rate in Nonproteinuric Patients with Type 1 Diabetes. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 706-713.	4.5	130
16	The early decline in renal function in patients with type 1 diabetes and proteinuria predicts the risk of end-stage renal disease. Kidney International, 2012, 82, 589-597.	5.2	120
17	Role of Podocyte B7-1 in Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2014, 25, 1415-1429.	6.1	114
18	Elevation of circulating TNF receptors 1 and 2 increases the risk of end-stage renal disease in American Indians with type 2 diabetes. Kidney International, 2015, 87, 812-819.	5.2	103

#	Article	IF	Citations
19	The Genetic Landscape of Renal Complications in Type 1 Diabetes. Journal of the American Society of Nephrology: JASN, 2017, 28, 557-574.	6.1	101
20	Markers of early progressive renal decline in typeÂ2Âdiabetes suggest different implications forÂetiological studies and prognostic testsÂdevelopment. Kidney International, 2018, 93, 1198-1206.	5.2	88
21	Circulating TGF-Î²1â€"Regulated miRNAs and the Risk of Rapid Progression to ESRD in Type 1 Diabetes. Diabetes, 2015, 64, 3285-3293.	0.6	85
22	Circulating miRNA Profiles Associated With Hyperglycemia in Patients With Type 1 Diabetes. Diabetes, 2018, 67, 1013-1023.	0.6	73
23	Serum Concentration of Cystatin C and Risk of End-Stage Renal Disease in Diabetes. Diabetes Care, 2012, 35, 2311-2316.	8.6	61
24	Tumor necrosis factor receptors 1 and 2 are associated with early glomerular lesions in type 2 diabetes. Kidney International, 2016, 89, 226-234.	5.2	57
25	Genetic susceptibility to nephropathy in insulinâ€dependent diabetes: From epidemiology to molecular genetics. Diabetes/metabolism Reviews, 1995, 11, 287-314.	0.3	48
26	Patterns of Estimated Glomerular Filtration Rate Decline Leading to End-Stage Renal Disease in Type 1 Diabetes. Diabetes Care, 2016, 39, 2262-2269.	8.6	46
27	Synergism Between Circulating Tumor Necrosis Factor Receptor 2 and HbA1c in Determining Renal Decline During 5â€"18 Years of Follow-up in Patients With Type 1 Diabetes and Proteinuria. Diabetes Care, 2014, 37, 2601-2608.	8.6	43
28	Cardiac Autonomic Neuropathy and Early Progressive Renal Decline in Patients with Nonmacroalbuminuric Type 1 Diabetes. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1136-1144.	4.5	41
29	Improved Glycemic Control and Risk of ESRD in Patients with Type 1 Diabetes and Proteinuria. Journal of the American Society of Nephrology: JASN, 2014, 25, 2916-2925.	6.1	39
30	Improved clinical trial enrollment criterion toÂidentify patients with diabetes at risk of end-stage renal disease. Kidney International, 2017, 92, 258-266.	5.2	38
31	Variations in Risk of End-Stage Renal Disease and Risk of Mortality in an International Study of Patients With Type 1 Diabetes and Advanced Nephropathy. Diabetes Care, 2019, 42, 93-101.	8.6	37
32	Profibrotic Circulating Proteins and Risk of Early Progressive Renal Decline in Patients With Type 2 Diabetes With and Without Albuminuria. Diabetes Care, 2020, 43, 2760-2767.	8.6	21
33	Comprehensive Search for Novel Circulating miRNAs and Axon Guidance Pathway Proteins Associated with Risk of ESKD in Diabetes. Journal of the American Society of Nephrology: JASN, 2021, 32, 2331-2351.	6.1	20
34	Progressive renal decline as the major feature of diabetic nephropathy in type 1 diabetes. Clinical and Experimental Nephrology, 2014, 18, 571-583.	1.6	18
35	Differential Gene Expression in Diabetic Nephropathy in Individuals With Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E876-E882.	3.6	18
36	Circulating proteins protect against renal decline and progression to end-stage renal disease in patients with diabetes. Science Translational Medicine, 2021, 13, .	12.4	18

#	Article	IF	Citations
37	Results of untargeted analysis using the SOMAscan proteomics platform indicates novel associations of circulating proteins with risk of progression to kidney failure in diabetes. Kidney International, 2022, 102, 370-381.	5.2	17
38	A profile of multiple circulating tumor necrosis factor receptors associated with early progressive kidney decline in Type 1 Diabetes is similar to profiles in autoimmune disorders. Kidney International, 2021, 99, 725-736.	5.2	11
39	Mutation Screening of the Neurogenin-3 Gene in Autosomal Dominant Diabetes1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 2320-2322.	3.6	9
40	Association of Coding Variants in Hydroxysteroid 17-beta Dehydrogenase 14 (HSD17B14) with Reduced Progression to End Stage Kidney Disease in Type 1 Diabetes. Journal of the American Society of Nephrology: JASN, 2021, 32, 2634-2651.	6.1	9
41	Molecular characterization of a DDEI melting polymorphism at the angiotensin I-converting enzyme (ACE) locus. Human Mutation, 1994, 4, 155-157.	2.5	6
42	High Risk of ESRD in Type 1 Diabetes: Call for Action: Introduction. Seminars in Nephrology, 2012, 32, 405-406.	1.6	4
43	Comments on Plasma Fibrinogen Levels Measured by Functional Methods. Thrombosis and Haemostasis, 1994, 72, 985-985.	3.4	3
44	Effect of TNFÎ± stimulation on expression of kidney risk inflammatory proteins in human umbilical vein endothelial cells cultured in hyperglycemia. Scientific Reports, 2021, 11, 11133.	3.3	2
45	Four RSAI restriction fragment melting polymorphisms in the region of the insulin receptor gene encoding for the alpha subunit. Clinical Genetics, 2008, 44, 279-280.	2.0	1
46	Ticlopidine May Reduce Functional Fibrinogen Levels by Inhibition of MPC Incorporation into Fibrin. Thrombosis and Haemostasis, 1997, 77, 603-604.	3.4	1
47	A database of naturally occurring human urinary peptides and proteins for use in clinical applications. Nature Precedings, 2007, , .	0.1	0
48	New Frontiers: Approaches to Understand the Mechanistic Basis of Renal Toxicity. Toxicologic Pathology, 2018, 46, 1002-1005.	1.8	0